Predictive Oncology (FRA:S1K) Total Stockholders Equity : €3.73 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Predictive Oncology Total Stockholders Equity?

Predictive Oncology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €3.73 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Predictive Oncology's Book Value per Share for the quarter that ended in Mar. 2024 was €0.92. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Predictive Oncology's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.64.

Predictive Oncology Total Stockholders Equity Historical Data

The historical data trend for Predictive Oncology's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Total Stockholders Equity Chart

Predictive Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

10.11

2.17

35.64

20.55

7.59

Predictive Oncology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															17.33	13.57	10.92	7.59	3.73

Predictive Oncology (FRA:S1K) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Predictive Oncology's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3.73	-	0.001)	/	4.03329
	=	0.92

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Predictive Oncology's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.532	+	1.865)	/	3.73
	=	0.64

Predictive Oncology Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Oncology (FRA:S1K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (FRA:S1K) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

POAI:USA

Address

2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121

Website

https://www.predictive-oncology.com

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Predictive Oncology (FRA:S1K) Headlines

No Headlines